Published in

American Association for Cancer Research, Clinical Cancer Research, p. OF1-OF4, 2023

DOI: 10.1158/1078-0432.ccr-22-3882

Links

Tools

Export citation

Search in Google Scholar

Scratching the Surface: NECTIN-4 as a Surrogate for Enfortumab Vedotin Resistance

Journal article published in 2023 by David H. Aggen ORCID, Carissa E. Chu ORCID, Jonathan E. Rosenberg ORCID
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Summary Clinical data with enfortumab vedotin (EV) suggest that most bladder cancers overexpress NECTIN-4. A recent article shows that NECTIN-4 membranous expression changes with progression to metastatic disease and that low NECTIN-4 expression in metastatic biopsies is potentially associated with EV resistance. These data argue for incorporation of NECTIN-4 expression into future biomarker strategies. See related article by Klümper et al., p. xxx